Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year High – Time to Buy?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reached a new 52-week high on Monday . The company traded as high as $546.17 and last traded at $525.6690, with a volume of 654559 shares. The stock had previously closed at $496.07.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: 2026 outlook raised: Vertex reported second-quarter revenue of approximately $3.3 billion and raised its full-year 2026 revenue guidance, supported by continued strength in newer products. The update reinforced the company’s growth outlook beyond its core cystic fibrosis medicines. Vertex Q2 2026 Earnings Call Transcript
• Positive Sentiment: Rival CF setback reduces competitive pressure: Sionna Therapeutics’ disappointing clinical-trial results for its cystic fibrosis treatment removed an immediate threat to Vertex’s dominant CF franchise, which generates most of the company’s revenue. Investors viewed the development as supportive of Vertex’s long-term market position. Vertex Stock Jumps as Rival Cystic Fibrosis Drug Fails
• Positive Sentiment: Pipeline catalysts remain in focus: Vertex is among several biotechnology companies with important 2026 catalysts, including potential regulatory decisions and late-stage clinical readouts. Successful developments could diversify revenue and support the stock’s premium valuation. Four Biotech Stocks With Major Second-Half Pipeline Catalysts
• Neutral Sentiment: Short-interest data is not informative: Reported short interest was zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. The figures appear anomalous and do not provide a meaningful signal about investor positioning.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on VRTX shares. Barclays increased their price objective on shares of Vertex Pharmaceuticals from $615.00 to $617.00 and gave the company an “overweight” rating in a report on Wednesday, August 5th. Morgan Stanley increased their target price on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a research report on Tuesday, May 5th. Weiss Ratings upgraded Vertex Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 5th. TD Cowen upped their target price on Vertex Pharmaceuticals from $525.00 to $550.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Finally, Wall Street Zen cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, June 28th. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $563.50.

Vertex Pharmaceuticals Price Performance

The company has a market cap of $134.43 billion, a PE ratio of 30.83, a price-to-earnings-growth ratio of 2.17 and a beta of 0.30. The company’s 50 day simple moving average is $478.64 and its two-hundred day simple moving average is $462.71.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, August 3rd. The pharmaceutical company reported $4.73 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01). The company had revenue of $3.33 billion during the quarter, compared to analysts’ expectations of $3.23 billion. Vertex Pharmaceuticals had a net margin of 35.00% and a return on equity of 23.09%. Vertex Pharmaceuticals’s revenue was up 12.5% on a year-over-year basis. During the same period last year, the firm posted $4.52 earnings per share. Sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 16.86 EPS for the current fiscal year.

Insider Activity at Vertex Pharmaceuticals

In related news, CMO Carmen Bozic sold 4,062 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $450.00, for a total transaction of $1,827,900.00. Following the sale, the chief marketing officer directly owned 16,953 shares of the company’s stock, valued at $7,628,850. This represents a 19.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total transaction of $787,485.00. Following the completion of the transaction, the executive vice president owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This trade represents a 3.20% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 10,464 shares of company stock worth $4,959,397 in the last three months. 0.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Meeder Asset Management Inc. acquired a new stake in Vertex Pharmaceuticals in the second quarter valued at approximately $26,000. Community Financial Services Group LLC purchased a new position in Vertex Pharmaceuticals in the second quarter worth approximately $26,000. Elevation Wealth Partners LLC grew its holdings in Vertex Pharmaceuticals by 103.7% during the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 28 shares in the last quarter. Motiv8 Investments LLC acquired a new position in Vertex Pharmaceuticals during the 4th quarter worth approximately $26,000. Finally, Swiss RE Ltd. purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at approximately $28,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.